Viatris (VTRS) Competitors $10.30 -0.12 (-1.10%) As of 10:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTRS vs. PFE, TAK, ARGX, ONC, BNTX, INSM, TEVA, SMMT, GMAB, and RDYShould you be buying Viatris stock or one of its competitors? The main competitors of Viatris include Pfizer (PFE), Takeda Pharmaceutical (TAK), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "medical" sector. Viatris vs. Its Competitors Pfizer Takeda Pharmaceutical argenex BeOne Medicines BioNTech Insmed Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Dr. Reddy's Laboratories Pfizer (NYSE:PFE) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations. Do insiders and institutionals hold more shares of PFE or VTRS? 68.4% of Pfizer shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 0.1% of Pfizer shares are held by insiders. Comparatively, 0.1% of Viatris shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings and valuation, PFE or VTRS? Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPfizer$63.63B2.21$8.03B$1.8813.16Viatris$14.74B0.82-$634.20M-$2.90-3.56 Is PFE or VTRS more profitable? Pfizer has a net margin of 16.84% compared to Viatris' net margin of -24.57%. Pfizer's return on equity of 21.42% beat Viatris' return on equity.Company Net Margins Return on Equity Return on Assets Pfizer16.84% 21.42% 9.12% Viatris -24.57%16.54%7.06% Does the media prefer PFE or VTRS? In the previous week, Pfizer had 62 more articles in the media than Viatris. MarketBeat recorded 65 mentions for Pfizer and 3 mentions for Viatris. Pfizer's average media sentiment score of 1.15 beat Viatris' score of 0.55 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 47 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Viatris 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is PFE or VTRS a better dividend stock? Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.0%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 4.7%. Pfizer pays out 91.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viatris pays out -16.6% of its earnings in the form of a dividend. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Do analysts recommend PFE or VTRS? Pfizer currently has a consensus price target of $28.12, suggesting a potential upside of 13.63%. Viatris has a consensus price target of $10.40, suggesting a potential upside of 0.82%. Given Pfizer's stronger consensus rating and higher possible upside, equities research analysts plainly believe Pfizer is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pfizer 1 Sell rating(s) 11 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 2.39Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Which has more volatility and risk, PFE or VTRS? Pfizer has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500. SummaryPfizer beats Viatris on 16 of the 20 factors compared between the two stocks. Get Viatris News Delivered to You Automatically Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTRS vs. The Competition Export to ExcelMetricViatrisMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.01B$7.66B$5.76B$9.78BDividend Yield4.61%2.74%3.95%4.02%P/E Ratio-3.5577.0530.8026.45Price / Sales0.8245.29466.65121.64Price / Cash2.0424.8337.7659.36Price / Book0.7721.9910.216.69Net Income-$634.20M$242.04M$3.26B$265.42M7 Day Performance-3.51%1.83%3.14%3.41%1 Month Performance11.39%0.50%4.36%1.09%1 Year Performance-13.32%11.84%45.22%23.47% Viatris Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTRSViatris1.9548 of 5 stars$10.32-1.0%$10.40+0.8%-10.9%$12.01B$14.74B-3.5532,000PFEPfizer4.8835 of 5 stars$25.07-0.3%$28.12+12.2%-13.0%$142.54B$63.63B13.3481,000Positive NewsTAKTakeda Pharmaceutical1.7902 of 5 stars$15.18+1.2%N/A-0.6%$48.31B$30.09B50.6147,455ARGXargenex3.0878 of 5 stars$661.32+1.1%$746.81+12.9%+37.0%$40.47B$2.25B33.911,599Trending NewsAnalyst ForecastAnalyst RevisionONCBeOne Medicines1.4279 of 5 stars$319.32-0.6%$330.89+3.6%N/A$35.00B$3.81B-184.5811,000BNTXBioNTech2.892 of 5 stars$112.55-0.9%$135.80+20.7%+18.3%$27.06B$2.98B-70.346,772Positive NewsINSMInsmed3.7836 of 5 stars$127.27-0.4%$129.57+1.8%+74.5%$26.90B$363.71M-22.291,271TEVATeva Pharmaceutical Industries3.4401 of 5 stars$18.08+1.2%$24.71+36.7%-3.7%$20.74B$16.54B-113.0036,830Positive NewsSMMTSummit Therapeutics2.2465 of 5 stars$26.29-1.5%$35.00+33.1%+84.2%$19.53BN/A-26.03110Positive NewsAnalyst ForecastGap DownGMABGenmab A/S3.5947 of 5 stars$23.42+0.5%$37.60+60.5%-11.2%$15.02B$3.12B11.772,682News CoverageRDYDr. Reddy's Laboratories2.9416 of 5 stars$14.26+0.2%$16.95+18.9%-13.7%$11.90B$3.81B21.6027,811News CoveragePositive News Related Companies and Tools Related Companies Pfizer Alternatives Takeda Pharmaceutical Alternatives argenex Alternatives BeOne Medicines Alternatives BioNTech Alternatives Insmed Alternatives Teva Pharmaceutical Industries Alternatives Summit Therapeutics Alternatives Genmab A/S Alternatives Dr. Reddy's Laboratories Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTRS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viatris Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viatris With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.